ALP was founded as a lipid and medical biochemistry research company in 2008 to specifically advance new research in the area of fatty liver disease and related lipid metabolism. Fatty liver disease is an emerging global epidemic in both the developed and emerging world. ALP research is focused on novel nutritional based methods of addressing the growing evidence of the connection between chronic inflammatory diseases and various stages of fatty liver disease. The ALP mission is to conduct lipid research and offer or license new products addressing chronic inflammatory diseases, and provide nutritional medicine based education to physicians and patients.